Quest Diagnostics, Inc. (DGX) is a company that has clearly picked up substantial movements in terms of
stock sales and purchases, as well as
insider trading activities. Several high-ranking executives have reportedly disposed of DGX shares, including Patrick Plewman, who sold 2,855 shares, and several EVPs and SVPs who also sold shares, sometimes to cover tax obligations. At the same time, investment firms like Victory Capital Management Inc. and Bahl & Gaynor Inc. have reduced their holdings in DGX, while others like American Century Companies Inc. and Mitsubishi UFJ Asset Management Co. have increased their stakes. On the business front, Quest Diagnostics has released AI companions to help
patients understand lab test results, unveiled a
novel Flow Cytometry MRD blood test for Myeloma, and launched advanced
Pharmacogenomics (PGx) offering. The firm consistently beats earnings estimates, with the most recent prediction of another triumph in the upcoming report. Most notably, the company's stock hit a 52-week high, thanks to its robust outlook.
Quest Diagnostics DGX News Analytics from Wed, 09 Jul 2025 07:00:00 GMT to Sat, 07 Mar 2026 09:02:34 GMT -
Rating 3
- Innovation 5
- Information 7
- Rumor 1
